Cytomegalovirus Infection Pipeline

DelveInsight’s “Cytomegalovirus (CMV) Infection Pipeline Insights, 2021” report provides in-depth analysis of the current clinical development landscape and future growth opportunities for the Cytomegalovirus (CMV) Infection industry. The disease description and Cytomegalovirus (CMV) Infection treatment guidelines are included in a clear image of the Cytomegalovirus (CMV) Infection pipeline landscape.

Some of the Key Highlights from the Cytomegalovirus Infection Pipeline Report

• Synklino, SpyBiotech, VBI Vaccines, Microbiotix, Nobelpharma, Moderna, Takeda, and others are among the companies developing new drug candidates to improve the Cytomegalovirus Infection pipeline landscape.

• Emerging therapy including Maribavir is in Phase III trials for Cytomegalovirus Infection whereas therapies including mRNA-1647 and NPC-21 are in the Phase II trials of development for Cytomegalovirus Infection.

• Some Cytomegalovirus Infection pipeline therapies such as VBI-1501 and MBX-400 are in the early stage of development i.e Phase I of clinical trials.

• There are some Cytomegalovirus Infection therapies also, such as SYN002 and Cytomegalovirus vaccine which are still in the preclinical stage.

For more information request sample @ Cytomegalovirus Infection Pipeline Insights

Cytomegalovirus Infection: Disease Overview

Infection with the Cytomegalovirus (CMV) is very common. CMV is easily transmitted via the saliva or other bodily fluids of an infected individual. It has nothing to do with the herpes virus, which causes cold sores. There are various types of Cytomegalovirus Infection:

• Congenital

• Primary

• Reactivation

Cytomegalovirus Infection: Symptoms

General symptoms of Primary CMV:

• Fatigue

• Swollen glands

• Fever

• Sore throat

• Muscle aches

Symptoms of Congenital CMV:

• Premature delivery

• Small size or low birth weight

• Bruise-like rashes

• Yellow skin or eyes (jaundice)

• Swollen liver and spleen

• Small head (microcephaly)

• Seizures

Cytomegalovirus Infection: Treatment

In most cases, treatment is not needed for healthy children and adults. CMV mononucleosis in healthy adults typically goes away without treatment. When a newborn or someone with a compromised immune system develops signs of CMV infection, they need to be treated. The type of treatment is determined by the severity of the signs and symptoms. The most popular form of treatment is antiviral medication.

Learn more about CMV @ Cytomegalovirus Infection Causes, Diagnosis and Treatment Landscape

Cytomegalovirus Infection Pipeline Analysis: Drug Profile

mRNA-1647: Moderna

mRNA-1647 is a vaccine that combines six mRNAs encoding two antigens into a single vaccine to protect against CMV infection. Five of the six mRNAs encode CMV pentamer complex subunits, while one mRNA encodes the glycoprotein B (gB) protein, both of which are immunogenic. CMV entry into a variety of cells, including epithelial cells, is dependent on the pentamer complex, while gB is required for entry into all susceptible cells, including fibroblasts. A vaccine that induces an immune response to both pentamer and gB could prevent CMV from infecting a variety of target cell types, preventing both primary and congenital infections.

Cytomegalovirus Infection Pipeline Therapies and Key Companies

• Maribavir: Takeda

• mRNA-1647: Moderna

• NPC-21: Nobelpharma

• VBI-1501: VBI Vaccines

• MBX-400: Microbiotix

• SYN002: Synklino

• Cytomegalovirus vaccine: SpyBiotech

Cytomegalovirus Infection Therapeutics Assessment

• By Product Type

• Monotherapy

• Combination Therapy

• By Stage

• Discovery

• Pre-Clinical

• Phase I

• Phase II

• Phase III

• Pre-registration

• By Route of Administration

• Inhalation

• Intravenous

• Oral

• Subcutaneous

• By Molecule Type

• Small Molecule

• Stem Cell Therapy

• Gene Therapy

• Targets

• Immune System

• Multiple Kinase

• By Mechanism of Action

• Protease Inhibitors

• Immunomodulatory

Scope of the Report

Coverage: Global

CMV Key Players: Synklino, SpyBiotech, VBI Vaccines, Microbiotix, Nobelpharma, Moderna, Takeda, among others

CMV Pipeline Therapies: Maribavir, mRNA-1647, NPC-21, VBI-1501, MBX-400, SYN002, Cytomegalovirus vaccine, others

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Key Questions Answered in the Cytomegalovirus Infection Report

• What are the options for treating  Cytomegalovirus infection?

• How many firms are working on therapies for Cytomegalovirus Infection?

• What are the most common therapies developed by these firms?

• What is the total number of Cytomegalovirus Infection therapies developed by each company?

• How many new Cytomegalovirus Infection treatments are being established for Cytomegalovirus Infection in its early, middle, and late stages?

• How many of the pipeline medications are available as monotherapies or in conjunction with other treatments?

• What are the most significant industry-industry and industry-academy partnerships, mergers and acquisitions, and significant licencing practises that will have an effect on Cytomegalovirus Infection?

Related Reports

Cyclin-Dependent Kinase Inhibitor Pipeline Insights

Get comprehensive analysis of Cyclin-Dependent Kinase Inhibitor  pipeline therapies and key companies including Roche,  Teijin Pharma, Cyclacel Pharmaceuticals, Bayer Schering Pharma, Merck & Co, Astex Therapeutics, among others. 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/